Physician profile
Bachar Samra
NPI 1699115824
$3,098.31
in general payments reported to CMS, 2019-2025
21 companies · $1,764 in 2025
The $1,764 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $12.45 · 2022: $14.32 · 2023: $160 · 2024: $984 · 2025: $1,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,075 · Food and Beverage: $763 · Education: $69.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,075.00 |
| Food and Beverage | $763.43 |
| Education | $69.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,225.78 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $200.69 | 2023-2025 | |
| Gilead Sciences, INC. | $185.32 | 2024-2025 | Trodelvy |
| Pfizer INC. | $127.88 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $58.71 | 2024 | Ultomiris |
| Servier Pharmaceuticals LLC | $26.95 | 2025 | |
| Kite Pharma, INC. | $23.96 | 2024 | Yescarta |
| Array Biopharma INC | $22.49 | 2024 | Mektovi, Braftovi, Tukysa |
| Glaxosmithkline, LLC. | $22.16 | 2024 | Ojjaara |
| Mirati Therapeutics, INC. | $21.47 | 2024 | Krazati |
| Taiho Oncology, INC. | $20.81 | 2024 | |
| Celgene Corporation | $20.76 | 2019 | |
| Janssen Biotech, INC. | $19.24 | 2023 | Imbruvica |
| Astellas Pharma US INC | $18.87 | 2023 | Xtandi |
| Pharmacyclics LLC, An Abbvie Company | $17.63 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $16.27 | 2023 | Adcetris |
| Springworks Therapeutics, INC. | $14.73 | 2024 | Ogsiveo |
| Daiichi Sankyo INC. | $14.32 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.12 | 2024 | |
| Beigene USA, INC. | $13.70 | 2024 | Tevimbra |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bachar Samra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.